GABBR2 and in situ carcinoma: There are clear expression differences between clinicogeneticsubgroups, consistent both with the ANOVA analysis of CIS gene expression acrosssubgroups (Table 2) and with the presence of genespreviously shown to be highly expressed in Group 3 and 4 tumours (e.g.NEUROD2, GABBR2[38]).